1h Free Analyst Time
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Graft Versus Host Disease (GVHD) - Drugs In Development, 2022, provides an overview of the Graft Versus Host Disease (GVHD) (Immunology) pipeline landscape.Speak directly to the analyst to clarify any post sales queries you may have.
Graft-versus-host disease (GVHD) is a complication that can occur after a stem cell or bone marrow transplant in which the newly transplanted donor cells attack the transplant recipient's body. Symptoms include abdominal pain or cramps, nausea, vomiting, and diarrhea, dry or irritated eyes, jaundice, shortness of breath, vaginal dryness and weight loss. Treatment includes immunosuppressants.
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Graft Versus Host Disease (GVHD) - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Graft Versus Host Disease (GVHD) (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Graft Versus Host Disease (GVHD) (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Graft Versus Host Disease (GVHD) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 5, 2, 11, 31, 28, 4, 63, 11 and 1 respectively. Similarly, the Universities portfolio in Phase III, Phase I, Preclinical and Discovery stages comprises 1, 2, 13 and 2 molecules, respectively.
Graft Versus Host Disease (GVHD) (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Graft Versus Host Disease (GVHD) (Immunology).
- The pipeline guide reviews pipeline therapeutics for Graft Versus Host Disease (GVHD) (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Graft Versus Host Disease (GVHD) (Immunology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Graft Versus Host Disease (GVHD) (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Graft Versus Host Disease (GVHD) (Immunology)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Graft Versus Host Disease (GVHD) (Immunology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Graft Versus Host Disease (GVHD) (Immunology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
- Introduction
- REPORT COVERAGE
- Graft Versus Host Disease (GVHD) - Overview
- Graft Versus Host Disease (GVHD) - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Graft Versus Host Disease (GVHD) - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Graft Versus Host Disease (GVHD) - Companies Involved in Therapeutics Development
- Graft Versus Host Disease (GVHD) - Drug Profiles
- Graft Versus Host Disease (GVHD) - Dormant Projects
- Graft Versus Host Disease (GVHD) - Discontinued Products
- Graft Versus Host Disease (GVHD) - Product Development Milestones
- Featured News & Press Releases
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact the Publisher
- Disclaimer
List of Tables
- Number of Products under Development for Graft Versus Host Disease (GVHD), 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Products under Development by Companies, 2022
- Products under Development by Universities/Institutes, 2022
- Number of Products by Stage and Target, 2022
- Number of Products by Stage and Mechanism of Action, 2022
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
- Graft Versus Host Disease (GVHD) - Pipeline by 9 Meters Biopharma Inc, 2022
- Graft Versus Host Disease (GVHD) - Pipeline by Abbisko Cayman Limited, 2022
- Graft Versus Host Disease (GVHD) - Pipeline by AbbVie Inc, 2022
- Graft Versus Host Disease (GVHD) - Pipeline by Accro BioScience (Suzhou) Co Ltd, 2022
- Graft Versus Host Disease (GVHD) - Pipeline by Actitrexx GmbH, 2022
- Graft Versus Host Disease (GVHD) - Pipeline by Adienne Pharma & Biotech SA, 2022
- Graft Versus Host Disease (GVHD) - Pipeline by Alphamab Oncology, 2022
- Graft Versus Host Disease (GVHD) - Pipeline by AltruBio Inc, 2022
- Graft Versus Host Disease (GVHD) - Pipeline by Amcyte Pharma Inc, 2022
- Graft Versus Host Disease (GVHD) - Pipeline by Amgen Inc, 2022
- Graft Versus Host Disease (GVHD) - Pipeline by AnaMar AB, 2022
- Graft Versus Host Disease (GVHD) - Pipeline by AnaptysBio Inc, 2022
- Graft Versus Host Disease (GVHD) - Pipeline by ASC Therapeutics Inc, 2022
- Graft Versus Host Disease (GVHD) - Pipeline by AstraZeneca Plc, 2022
- Graft Versus Host Disease (GVHD) - Pipeline by Athos Therapeutics Inc, 2022
- Graft Versus Host Disease (GVHD) - Pipeline by Autolus Therapeutics Plc, 2022
- Graft Versus Host Disease (GVHD) - Pipeline by Avalon GloboCare Corp, 2022
- Graft Versus Host Disease (GVHD) - Pipeline by Bellicum Pharmaceuticals Inc, 2022
- Graft Versus Host Disease (GVHD) - Pipeline by Biocon Ltd, 2022
- Graft Versus Host Disease (GVHD) - Pipeline by Biogen Inc, 2022
- Graft Versus Host Disease (GVHD) - Pipeline by BioIncept LLC, 2022
- Graft Versus Host Disease (GVHD) - Pipeline by BlueRock Therapeutics LLC, 2022
- Graft Versus Host Disease (GVHD) - Pipeline by BlueSphere Bio Inc, 2022
- Graft Versus Host Disease (GVHD) - Pipeline by Boryung ViGenCell Inc, 2022
- Graft Versus Host Disease (GVHD) - Pipeline by Bristol-Myers Squibb Co, 2022
- Graft Versus Host Disease (GVHD) - Pipeline by Capricor Therapeutics Inc, 2022
- Graft Versus Host Disease (GVHD) - Pipeline by Cellective BioTherapy Inc, 2022
- Graft Versus Host Disease (GVHD) - Pipeline by Cellenkos Inc, 2022
- Graft Versus Host Disease (GVHD) - Pipeline by Cellestia Biotech AG, 2022
- Graft Versus Host Disease (GVHD) - Pipeline by Cellix Bio Pvt Ltd, 2022
- Graft Versus Host Disease (GVHD) - Pipeline by CELLnLIFE Inc, 2022
- Graft Versus Host Disease (GVHD) - Pipeline by Celltrion Inc, 2022
- Graft Versus Host Disease (GVHD) - Pipeline by Cellvation Inc, 2022
- Graft Versus Host Disease (GVHD) - Pipeline by CheckPoint Immunology Inc, 2022
- Graft Versus Host Disease (GVHD) - Pipeline by Claritas Pharmaceuticals Inc, 2022
- Graft Versus Host Disease (GVHD) - Pipeline by Clinigen Ltd, 2022
- Graft Versus Host Disease (GVHD) - Pipeline by Connext Co Ltd, 2022
- Graft Versus Host Disease (GVHD) - Pipeline by Corvus Pharmaceuticals Inc, 2022
- Graft Versus Host Disease (GVHD) - Pipeline by CSL Ltd, 2022
- Graft Versus Host Disease (GVHD) - Pipeline by CTI BioPharma Corp, 2022
- Graft Versus Host Disease (GVHD) - Pipeline by Cue Biopharma Inc, 2022
- Graft Versus Host Disease (GVHD) - Pipeline by Cynata Therapeutics Ltd, 2022
- Graft Versus Host Disease (GVHD) - Pipeline by Cytopeutics Pte Ltd, 2022
- Graft Versus Host Disease (GVHD) - Pipeline by Daewoong Pharmaceutical Co Ltd, 2022
- Graft Versus Host Disease (GVHD) - Pipeline by Dianomi Therapeutics Inc, 2022
- Graft Versus Host Disease (GVHD) - Pipeline by Dualogics Corp, 2022
- Graft Versus Host Disease (GVHD) - Pipeline by Educell doo, 2022
- Graft Versus Host Disease (GVHD) - Pipeline by Eli Lilly and Co, 2022
- Graft Versus Host Disease (GVHD) - Pipeline by enGene Inc, 2022
- Graft Versus Host Disease (GVHD) - Pipeline by Equillium Inc, 2022
- Graft Versus Host Disease (GVHD) - Pipeline by EV Therapeutics Inc, 2022
- Graft Versus Host Disease (GVHD) - Pipeline by Evive Biotech, 2022
- Graft Versus Host Disease (GVHD) - Pipeline by ExCellThera Inc, 2022
- Graft Versus Host Disease (GVHD) - Pipeline by F. Hoffmann-La Roche Ltd, 2022
- Graft Versus Host Disease (GVHD) - Pipeline by Fate Therapeutics Inc, 2022
- Graft Versus Host Disease (GVHD) - Pipeline by Forte Biosciences Inc, 2022
- Graft Versus Host Disease (GVHD) - Pipeline by Genentech USA Inc, 2022
- Graft Versus Host Disease (GVHD) - Pipeline by Glia LLC, 2022
- Graft Versus Host Disease (GVHD) - Pipeline by Good T Cells Inc, 2022
- Graft Versus Host Disease (GVHD) - Pipeline by Grifols SA, 2022
- Graft Versus Host Disease (GVHD) - Pipeline by GSK plc, 2022
- Graft Versus Host Disease (GVHD) - Pipeline by Hangzhou East China Pharmaceutical Group Co Ltd, 2022
- Graft Versus Host Disease (GVHD) - Pipeline by Humanigen Inc, 2022
- Graft Versus Host Disease (GVHD) - Pipeline by iCELL Biotechnology Co Ltd, 2022
- Graft Versus Host Disease (GVHD) - Pipeline by Immplacate Inc, 2022
- Graft Versus Host Disease (GVHD) - Pipeline by Immune Modulation Inc, 2022
- Graft Versus Host Disease (GVHD) - Pipeline by ImmuneTarget Inc, 2022
- Graft Versus Host Disease (GVHD) - Pipeline by Imstem Biotechnology Inc, 2022
- Graft Versus Host Disease (GVHD) - Pipeline by Incyte Corp, 2022
- Graft Versus Host Disease (GVHD) - Pipeline by Inmagene Biopharmaceuticals Ltd, 2022
- Graft Versus Host Disease (GVHD) - Pipeline by Jazz Pharmaceuticals Plc, 2022
- Graft Versus Host Disease (GVHD) - Pipeline by JN Biosciences LLC, 2022
- Graft Versus Host Disease (GVHD) - Pipeline by Kadmon Holdings Inc, 2022
- Graft Versus Host Disease (GVHD) - Pipeline by Kamada Pharmaceuticals, 2022
- Graft Versus Host Disease (GVHD) - Pipeline by Kiniksa Pharmaceuticals Ltd, 2022
- Graft Versus Host Disease (GVHD) - Pipeline by Kymab Ltd, 2022
- Graft Versus Host Disease (GVHD) - Pipeline by MaaT Pharma, 2022
- Graft Versus Host Disease (GVHD) - Pipeline by Machavert Pharmaceuticals LLC, 2022
- Graft Versus Host Disease (GVHD) - Pipeline by Magenta Therapeutics Inc, 2022
- Graft Versus Host Disease (GVHD) - Pipeline by Mallinckrodt Plc, 2022
- Graft Versus Host Disease (GVHD) - Pipeline by Medexus Pharmaceuticals Inc, 2022
- Graft Versus Host Disease (GVHD) - Pipeline by Medicenna Therapeutics Corp, 2022
- Graft Versus Host Disease (GVHD) - Pipeline by Mediolanum farmaceutici SpA, 2022
- Graft Versus Host Disease (GVHD) - Pipeline by Medsenic SAS, 2022
- Graft Versus Host Disease (GVHD) - Pipeline by Merck & Co Inc, 2022
- Graft Versus Host Disease (GVHD) - Pipeline by Mereo Biopharma Group Plc, 2022
- Graft Versus Host Disease (GVHD) - Pipeline by Mesoblast Ltd, 2022
- Graft Versus Host Disease (GVHD) - Pipeline by Millennium Pharmaceuticals Inc, 2022
- Graft Versus Host Disease (GVHD) - Pipeline by MiNK Therapeutics Inc, 2022
- Graft Versus Host Disease (GVHD) - Pipeline by MitoImmune Therapeutics Inc, 2022
- Graft Versus Host Disease (GVHD) - Pipeline by Moderna Inc, 2022
- Graft Versus Host Disease (GVHD) - Pipeline by NapaJen Pharma Inc, 2022
- Graft Versus Host Disease (GVHD) - Pipeline by Neoleukin Therapeutics Inc, 2022
- Graft Versus Host Disease (GVHD) - Pipeline by Neovii Pharmaceuticals AG, 2022
- Graft Versus Host Disease (GVHD) - Pipeline by Nurix Therapeutics Inc, 2022
- Graft Versus Host Disease (GVHD) - Pipeline by OncoC4 Inc, 2022
- Graft Versus Host Disease (GVHD) - Pipeline by Orca Biosystems Inc, 2022
- Graft Versus Host Disease (GVHD) - Pipeline by OSE Immunotherapeutics SA, 2022
- Graft Versus Host Disease (GVHD) - Pipeline by Ossium Health Inc, 2022
- Graft Versus Host Disease (GVHD) - Pipeline by Panorama Researchama Research, 2022
- Graft Versus Host Disease (GVHD) - Pipeline by Pfizer Inc, 2022
- Graft Versus Host Disease (GVHD) - Pipeline by Platinum Biotech (Beijing) Co Ltd, 2022
- Graft Versus Host Disease (GVHD) - Pipeline by Pluristem Therapeutics Inc, 2022
- Graft Versus Host Disease (GVHD) - Pipeline by Precision Biosciences Inc, 2022
- Graft Versus Host Disease (GVHD) - Pipeline by Rebus Holdings Inc, 2022
- Graft Versus Host Disease (GVHD) - Pipeline by REGiMMUNE Corp, 2022
- Graft Versus Host Disease (GVHD) - Pipeline by Rheos Medicines Inc, 2022
- Graft Versus Host Disease (GVHD) - Pipeline by Sanofi, 2022
- Graft Versus Host Disease (GVHD) - Pipeline by SCM lifescience Co Ltd, 2022
- Graft Versus Host Disease (GVHD) - Pipeline by Seagen Inc, 2022
- Graft Versus Host Disease (GVHD) - Pipeline by Secura Bio Inc, 2022
- Graft Versus Host Disease (GVHD) - Pipeline by Seres Therapeutics Inc, 2022
- Graft Versus Host Disease (GVHD) - Pipeline by Shenzhen Chipscreen Biosciences Co Ltd, 2022
- Graft Versus Host Disease (GVHD) - Pipeline by Sino Biopharmaceutical Ltd, 2022
- Graft Versus Host Disease (GVHD) - Pipeline by Sorrento Therapeutics Inc, 2022
- Graft Versus Host Disease (GVHD) - Pipeline by STERO Biotechs Ltd, 2022
- Graft Versus Host Disease (GVHD) - Pipeline by StingInn LLC, 2022
- Graft Versus Host Disease (GVHD) - Pipeline by Suzhou Connect Biopharmaceuticals Ltd, 2022
- Graft Versus Host Disease (GVHD) - Pipeline by Suzhou Regend Therapeutics Co Ltd, 2022
- Graft Versus Host Disease (GVHD) - Pipeline by Suzhou Zelgen Biopharmaceutical Co Ltd, 2022
- Graft Versus Host Disease (GVHD) - Pipeline by Syndax Pharmaceuticals Inc, 2022
- Graft Versus Host Disease (GVHD) - Pipeline by Synthetic Biologics Inc, 2022
- Graft Versus Host Disease (GVHD) - Pipeline by Takeda Pharmaceutical Co Ltd, 2022
- Graft Versus Host Disease (GVHD) - Pipeline by Targazyme Inc, 2022
- Graft Versus Host Disease (GVHD) - Pipeline by TCF GmbH, 2022
- Graft Versus Host Disease (GVHD) - Pipeline by TCR2 Therapeutics Inc, 2022
- Graft Versus Host Disease (GVHD) - Pipeline by TeraImmune Inc, 2022
- Graft Versus Host Disease (GVHD) - Pipeline by Tianjin Angsai Cell Genetic Engineering Co Ltd, 2022
- Graft Versus Host Disease (GVHD) - Pipeline by TreeFrog Therapeutics SAS, 2022
- Graft Versus Host Disease (GVHD) - Pipeline by Triursus Therapeutics Inc, 2022
- Graft Versus Host Disease (GVHD) - Pipeline by United BioPharma Inc, 2022
- Graft Versus Host Disease (GVHD) - Pipeline by Vault Pharma Inc, 2022
- Graft Versus Host Disease (GVHD) - Pipeline by VectivBio Holding AG, 2022
- Graft Versus Host Disease (GVHD) - Pipeline by Vedanta Biosciences Inc, 2022
- Graft Versus Host Disease (GVHD) - Pipeline by Viracta Therapeutics Inc, 2022
- Graft Versus Host Disease (GVHD) - Pipeline by Visterra Inc, 2022
- Graft Versus Host Disease (GVHD) - Pipeline by VITRAC Therapeutics LLC, 2022
- Graft Versus Host Disease (GVHD) - Pipeline by Xbiome Co Ltd, 2022
- Graft Versus Host Disease (GVHD) - Pipeline by Xenikos BV, 2022
- Graft Versus Host Disease (GVHD) - Pipeline by Xenothera SAS, 2022
- Graft Versus Host Disease (GVHD) - Dormant Projects, 2022
- Graft Versus Host Disease (GVHD) - Discontinued Products, 2022
List of Figures
- Number of Products under Development for Graft Versus Host Disease (GVHD), 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Number of Products by Top 10 Targets, 2022
- Number of Products by Stage and Top 10 Targets, 2022
- Number of Products by Top 10 Mechanism of Actions, 2022
- Number of Products by Stage and Top 10 Mechanism of Actions, 2022
- Number of Products by Top 10 Routes of Administration, 2022
- Number of Products by Stage and Top 10 Routes of Administration, 2022
- Number of Products by Top 10 Molecule Types, 2022
- Number of Products by Stage and Top 10 Molecule Types, 2022
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- 9 Meters Biopharma Inc
- Abbisko Cayman Limited
- AbbVie Inc
- Accro BioScience (Suzhou) Co Ltd
- Actitrexx GmbH
- Adienne Pharma & Biotech SA
- Alphamab Oncology
- AltruBio Inc
- Amcyte Pharma Inc
- Amgen Inc
- AnaMar AB
- AnaptysBio Inc
- ASC Therapeutics Inc
- AstraZeneca Plc
- Athos Therapeutics Inc
- Autolus Therapeutics Plc
- Avalon GloboCare Corp
- Bellicum Pharmaceuticals Inc
- Biocon Ltd
- Biogen Inc
- BioIncept LLC
- BlueRock Therapeutics LLC
- BlueSphere Bio Inc
- Boryung ViGenCell Inc
- Bristol-Myers Squibb Co
- Capricor Therapeutics Inc
- Cellective BioTherapy Inc
- Cellenkos Inc
- Cellestia Biotech AG
- Cellix Bio Pvt Ltd
- CELLnLIFE Inc
- Celltrion Inc
- Cellvation Inc
- CheckPoint Immunology Inc
- Claritas Pharmaceuticals Inc
- Clinigen Ltd
- Connext Co Ltd
- Corvus Pharmaceuticals Inc
- CSL Ltd
- CTI BioPharma Corp
- Cue Biopharma Inc
- Cynata Therapeutics Ltd
- Cytopeutics Pte Ltd
- Daewoong Pharmaceutical Co Ltd
- Dianomi Therapeutics Inc
- Dualogics Corp
- Educell doo
- Eli Lilly and Co
- enGene Inc
- Equillium Inc
- EV Therapeutics Inc
- Evive Biotech
- ExCellThera Inc
- F. Hoffmann-La Roche Ltd
- Fate Therapeutics Inc
- Forte Biosciences Inc
- Genentech USA Inc
- Glia LLC
- Good T Cells Inc
- Grifols SA
- GSK plc
- Hangzhou East China Pharmaceutical Group Co Ltd
- Humanigen Inc
- iCELL Biotechnology Co Ltd
- Immplacate Inc
- Immune Modulation Inc
- ImmuneTarget Inc
- Imstem Biotechnology Inc
- Incyte Corp
- Inmagene Biopharmaceuticals Ltd
- Jazz Pharmaceuticals Plc
- JN Biosciences LLC
- Kadmon Holdings Inc
- Kamada Pharmaceuticals
- Kiniksa Pharmaceuticals Ltd
- Kymab Ltd
- MaaT Pharma
- Machavert Pharmaceuticals LLC
- Magenta Therapeutics Inc
- Mallinckrodt Plc
- Medexus Pharmaceuticals Inc
- Medicenna Therapeutics Corp
- Mediolanum farmaceutici SpA
- Medsenic SAS
- Merck & Co Inc
- Mereo Biopharma Group Plc
- Mesoblast Ltd
- Millennium Pharmaceuticals Inc
- MiNK Therapeutics Inc
- MitoImmune Therapeutics Inc
- Moderna Inc
- NapaJen Pharma Inc
- Neoleukin Therapeutics Inc
- Neovii Pharmaceuticals AG
- Nurix Therapeutics Inc
- OncoC4 Inc
- Orca Biosystems Inc
- OSE Immunotherapeutics SA
- Ossium Health Inc
- Panorama Researchama Research
- Pfizer Inc
- Platinum Biotech (Beijing) Co Ltd
- Pluristem Therapeutics Inc
- Precision Biosciences Inc
- Rebus Holdings Inc
- REGiMMUNE Corp
- Rheos Medicines Inc
- Sanofi
- SCM lifescience Co Ltd
- Seagen Inc
- Secura Bio Inc
- Seres Therapeutics Inc
- Shenzhen Chipscreen Biosciences Co Ltd
- Sino Biopharmaceutical Ltd
- Sorrento Therapeutics Inc
- STERO Biotechs Ltd
- StingInn LLC
- Suzhou Connect Biopharmaceuticals Ltd
- Suzhou Regend Therapeutics Co Ltd
- Suzhou Zelgen Biopharmaceutical Co Ltd
- Syndax Pharmaceuticals Inc
- Synthetic Biologics Inc
- Takeda Pharmaceutical Co Ltd
- Targazyme Inc
- TCF GmbH
- TCR2 Therapeutics Inc
- TeraImmune Inc
- Tianjin Angsai Cell Genetic Engineering Co Ltd
- TreeFrog Therapeutics SAS
- Triursus Therapeutics Inc
- United BioPharma Inc
- Vault Pharma Inc
- VectivBio Holding AG
- Vedanta Biosciences Inc
- Viracta Therapeutics Inc
- Visterra Inc
- VITRAC Therapeutics LLC
- Xbiome Co Ltd
- Xenikos BV
- Xenothera SAS
